158 related articles for article (PubMed ID: 21049464)
1. Treatment with sorafenib in advanced thyroid cancer - a case report.
Krajewska J; Olczyk T; Roskosz J; Paliczk-Cieślik E; Smietana AK; Kaczmarek-Borowska B; Jarząb B
Endokrynol Pol; 2010; 61(5):492-6. PubMed ID: 21049464
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
[TBL] [Abstract][Full Text] [Related]
3. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
Chen L; Shen Y; Luo Q; Yu Y; Lu H; Zhu R
Thyroid; 2011 Feb; 21(2):119-24. PubMed ID: 21186953
[TBL] [Abstract][Full Text] [Related]
4. Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Crouzeix G; Michels JJ; Sevin E; Aide N; Vaur D; Bardet S;
J Clin Endocrinol Metab; 2012 Sep; 97(9):3046-50. PubMed ID: 22723320
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report.
Higuchi Y; Motoki T; Ishida H; Kanamitsu K; Washio K; Oyama T; Noda T; Tsurumaru Y; Okada A; Tsukahara H; Shimada A
BMC Cancer; 2017 Nov; 17(1):775. PubMed ID: 29162036
[TBL] [Abstract][Full Text] [Related]
6. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
[TBL] [Abstract][Full Text] [Related]
7. Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib.
Shen Y; Ruan M; Luo Q; Yu Y; Lu H; Zhu R; Chen L
Thyroid; 2012 Aug; 22(8):856-60. PubMed ID: 22793259
[TBL] [Abstract][Full Text] [Related]
8. Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer.
Danilovic DLS; Castro G; Roitberg FSR; Vanderlei FAB; Bonani FA; Freitas RMC; Coura-Filho GB; Camargo RY; Kulcsar MA; Marui S; Hoff AO
Arch Endocrinol Metab; 2018 Jun; 62(3):370-375. PubMed ID: 29791660
[TBL] [Abstract][Full Text] [Related]
9. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.
Waguespack SG; Sherman SI; Williams MD; Clayman GL; Herzog CE
Thyroid; 2009 Apr; 19(4):407-12. PubMed ID: 19355831
[TBL] [Abstract][Full Text] [Related]
10. Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
Iyer P; Mayer JL; Ewig JM
Thyroid; 2014 Jan; 24(1):169-74. PubMed ID: 23544852
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
Hoftijzer H; Heemstra KA; Morreau H; Stokkel MP; Corssmit EP; Gelderblom H; Weijers K; Pereira AM; Huijberts M; Kapiteijn E; Romijn JA; Smit JW
Eur J Endocrinol; 2009 Dec; 161(6):923-31. PubMed ID: 19773371
[TBL] [Abstract][Full Text] [Related]
12. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
[TBL] [Abstract][Full Text] [Related]
14. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
Toubert ME; Vercellino L; Faugeron I; Lussato D; Hindie E; Bousquet G
Thyroid; 2011 Apr; 21(4):451-4. PubMed ID: 21385075
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Hong DS; Cabanillas ME; Wheler J; Naing A; Tsimberidou AM; Ye L; Busaidy NL; Waguespack SG; Hernandez M; El Naggar AK; Bidyasar S; Wright J; Sherman SI; Kurzrock R
J Clin Endocrinol Metab; 2011 Apr; 96(4):997-1005. PubMed ID: 21289252
[TBL] [Abstract][Full Text] [Related]
16. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
[TBL] [Abstract][Full Text] [Related]
17. Response to sorafenib treatment in advanced metastatic thyroid cancer.
Pitoia F
Arq Bras Endocrinol Metabol; 2014 Feb; 58(1):37-41. PubMed ID: 24728162
[TBL] [Abstract][Full Text] [Related]
18. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Hainsworth JD; Ervin T; Friedman E; Priego V; Murphy PB; Clark BL; Lamar RE
Cancer; 2010 Aug; 116(15):3663-9. PubMed ID: 20564147
[TBL] [Abstract][Full Text] [Related]
19. Distant, solitary skeletal muscle metastasis in recurrent papillary thyroid carcinoma.
Bae SY; Lee SK; Koo MY; Hur SM; Choi MY; Cho DH; Choe JH; Kim JH; Kim JS
Thyroid; 2011 Sep; 21(9):1027-31. PubMed ID: 21834676
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib therapy in metastatic papillary thyroid cancer.
Gori S; Foglietta J; Rossi M; Hamzaj A; Stocchi L; Galuppo C; Picece V; Puxeddu E; Furlani L
Tumori; 2013; 99(6):285e-7e. PubMed ID: 24503805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
